Algernon Pharmaceuticals Inc. (AGN.CN)
CAD 0.07
(0.0%)
CAD 0.07
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.98 Million CAD | 39.38% |
| 2022 | -6.01 Million CAD | 25.21% |
| 2021 | - CAD | 8.14% |
| 2020 | -8.53 Million CAD | -361.67% |
| 2019 | -1.86 Million CAD | -109.18% |
| 2018 | -896.64 Thousand CAD | -3.31% |
| 2017 | -1.26 Million CAD | -182.65% |
| 2016 | -2.76 Million CAD | 183478.76% |
| 2015 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -972.71 CAD | -93.78% |
| 2024 Q1 | -514.54 Thousand CAD | 45.18% |
| 2024 Q3 | -459.58 Thousand CAD | 53.87% |
| 2023 Q4 | -972.5 Thousand CAD | 12.8% |
| 2023 Q2 | -1.23 Million CAD | 33.89% |
| 2023 FY | - CAD | 39.38% |
| 2023 Q1 | -1.86 Million CAD | 14.65% |
| 2023 Q3 | -1.11 Million CAD | 9.72% |
| 2022 Q3 | -799.2 Thousand CAD | 56.48% |
| 2022 Q4 | -2.18 Million CAD | -173.93% |
| 2022 FY | - CAD | 25.21% |
| 2022 Q2 | -1.83 Million CAD | -52.92% |
| 2022 Q1 | -1.2 Million CAD | -119.95% |
| 2021 Q4 | -546.03 Thousand CAD | 67.43% |
| 2021 Q1 | -3.44 Million CAD | -20.36% |
| 2021 Q2 | -2.38 Million CAD | 30.59% |
| 2021 Q3 | -1.67 Million CAD | 29.81% |
| 2021 FY | - CAD | 8.14% |
| 2020 Q2 | -795.14 Thousand CAD | -129.57% |
| 2020 Q4 | -2.85 Million CAD | 40.04% |
| 2020 Q3 | -4.76 Million CAD | -499.56% |
| 2020 Q1 | -346.36 Thousand CAD | 18.74% |
| 2020 FY | - CAD | -361.67% |
| 2019 FY | - CAD | -109.18% |
| 2019 Q4 | -426.25 Thousand CAD | 19.07% |
| 2019 Q3 | -526.67 Thousand CAD | -19.46% |
| 2019 Q2 | -440.88 Thousand CAD | 12.65% |
| 2019 Q1 | -504.71 Thousand CAD | -174.87% |
| 2018 Q1 | -186.09 Thousand CAD | 34.49% |
| 2018 FY | - CAD | -3.31% |
| 2018 Q4 | -183.62 Thousand CAD | 52.58% |
| 2018 Q3 | -387.2 Thousand CAD | -156.97% |
| 2018 Q2 | -150.68 Thousand CAD | 19.03% |
| 2017 Q1 | -483.14 Thousand CAD | -110.09% |
| 2017 Q2 | -286.9 Thousand CAD | 40.62% |
| 2017 Q3 | 175.56 Thousand CAD | 161.19% |
| 2017 Q4 | -284.05 Thousand CAD | -261.8% |
| 2017 FY | - CAD | -182.65% |
| 2016 FY | - CAD | 183478.76% |
| 2016 Q4 | -229.97 Thousand CAD | 51.51% |
| 2016 Q3 | -474.25 Thousand CAD | 76.56% |
| 2016 Q2 | -2.02 Million CAD | -153.4% |
| 2016 Q1 | 3.78 Million CAD | 724339.39% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q4 | 523.00 CAD | 100.26% |
| 2015 Q3 | -203.79 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Asep Medical Holdings Inc | -8.13 Million CAD | 38.772% |
| BetterLife Pharma Inc. | -3.19 Million CAD | -56.087% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 35.199% |
| ChitogenX Inc. | -2.69 Million CAD | -84.909% |
| Rapid Dose Therapeutics Corp. | -3.02 Million CAD | -64.691% |
| Defence Therapeutics Inc. | -12.67 Million CAD | 60.701% |
| Entheon Biomedical Corp. | 13.99 Thousand CAD | 35699.65% |
| Gemina Laboratories Ltd. | -5.17 Million CAD | 3.755% |
| Glow Lifetech Corp. | -1.26 Million CAD | -294.402% |
| Lexston Life Sciences Corp. | -648.32 Thousand CAD | -668.359% |
| Pharmala Biotech Holdings Inc. | -710.18 Thousand CAD | -601.431% |
| Doseology Sciences Inc. | -319.47 Thousand CAD | -1459.249% |
| MYND Life Sciences Inc. | -1.82 Million CAD | -172.927% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | -314.328% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | -63.682% |
| PreveCeutical Medical Inc. | -955.08 Thousand CAD | -421.571% |
| Telescope Innovations Corp. | -5.49 Million CAD | 9.27% |